• Alias: ABT 869
    • VEGF and PDGF inhibitor
    • Exhibits potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FLT3
    • Potential for activity in AML patients
    • Currently in phase 2 trials for breast cancer, NSCLC, renal cell carcinoma, and KRAS–positive colorectal cancer; phase 3 trial for HCC
    • Phase 1/2 dose: 0.1 to 0.25 mg/kg PO daily
    • Half-life: A range of 15 to 19 hours
    • Metabolism: Extensive through CYP450, but no subfamilies elucidated to date
    • Common side effects: Hypertension, fatigue, nausea, diarrhea, decreased appetite, palmar–plantar erythrodysesthesia,
    Other topics in Targeted and Immunotherapy Agents